← Back
Lexaria Bioscience
LEXX
$3.30
+4.87% today
No insider bought or sold Lexaria Bioscience stock on the market in the last year.
◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
Reverse split 1-for-15 in Aug 2026. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what LEXX ever actually traded at. The drop is real, but those huge old numbers aren't.
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
No insider bought or sold Lexaria Bioscience stock on the market in the last year. The reports below are share awards and other paperwork.
All reports
Every insider trade and SEC report we hold for Lexaria Bioscience.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Jul 30, 2025BoughtChristopher BunkaJul 30, 2025 · Director+4.2%via a trust or family11,900 @ $0.9131$10.9K
Jul 30, 2025BoughtWilliam Edward McKechnieJul 30, 2025 · Traded Jul 29, 2025 · Director+28%5,000 @ $0.9063$4.5K
Jul 30, 2025BoughtJohn Martin DochertyJul 30, 2025 · Traded Jul 29, 2025 · President & CSO+100%5,376 @ $0.9280$5K
Jul 30, 2025BoughtVanessa CarleJul 30, 2025 · Traded Jul 29, 2025 · Secretary+100%750 @ $0.9100$682.50
Jul 30, 2025BoughtRichard ChristopherJul 30, 2025 · Traded Jul 29, 2025 · Chief Executive Officer+23%15,000 @ $0.9094$13.6K
1 more with Pro →Analysts, earnings and news
Analysts' price target
$52.50 average
2 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
3 of 4 quarters above
Q2 '26−$1.20 a share−$0.30
Q1 '26−$0.90 a share+$0.15
Q4 '25−$1.05 a share+$0.90
Q3 '25−$1.95 a share+$0.40